PolyMedix, Inc.(fka PYMXQ)

[gfp927z]

Partnering, from YH board -


http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_P/threadview?m=tm&bn=67574&tid=15270&mid=15276&tof=1&frt=2


>>> Poly has to WANT TO partner <<<



The financial realities mean that Nic now has to partner, no question about it. The only question is whether he'll do an ex-US deal in 2012 and the US deal in 2013, or do a comprehensive deal for full global rights in 2012.

If he can negotiate a co-promote option for the US and still get good strong upfronts, he may opt for a full global rights deal. That's the way to go IMO, and he can boost the deal terms even more by including in the deal ABSSSI plus Bacteremia and Endocarditis (with Pneumonia/Lung a possibility). The Pneumonia/Lung indications are especially valuable because Cubist's Daptomycin doesn't work in the lung.

PYMX can then advance Oral Mucositis as the main in-house program. In a year's time, PYMX could have up to FOUR Phase 2's ongoing, three with the partner (ABSSSI, Endocarditis, Bacteremia), and one in-house in Oral Mucositis. Pneumonia/Lung would be a potential 5th Phase 2 in 2013.

A company with three or four Phase 2 programs in the clinic in large indications (with ABSSSI starting pivotal Phase 3 in the second half of 2013) -- that company can realistically have a market cap in the $300 mil range or more.